Coherus BioSciences (NASDAQ:CHRS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock.

A number of other analysts have also recently commented on the company. UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $4.00 to $1.50 in a research report on Friday, August 16th. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Coherus BioSciences presently has an average rating of “Moderate Buy” and a consensus price target of $6.13.

Coherus BioSciences Stock Down 0.6 %

Shares of Coherus BioSciences stock traded down $0.01 during trading on Thursday, reaching $0.82. The company’s stock had a trading volume of 3,522,703 shares, compared to its average volume of 2,673,164. The company has a market cap of $93.90 million, a price-to-earnings ratio of -10.19 and a beta of 0.69. The firm’s 50-day moving average is $1.01 and its two-hundred day moving average is $1.46. Coherus BioSciences has a 52-week low of $0.66 and a 52-week high of $3.70.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10. The business had revenue of $64.98 million for the quarter, compared to analysts’ expectations of $57.08 million. On average, equities research analysts anticipate that Coherus BioSciences will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CHRS. Price T Rowe Associates Inc. MD increased its position in shares of Coherus BioSciences by 32.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 7,608 shares during the last quarter. Hsbc Holdings PLC raised its stake in shares of Coherus BioSciences by 10.6% in the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 9,905 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Coherus BioSciences by 6.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 209,460 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 13,250 shares during the period. Nisa Investment Advisors LLC lifted its stake in Coherus BioSciences by 2,672.8% in the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 19,912 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of Coherus BioSciences during the 1st quarter worth approximately $56,000. Institutional investors own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.